To investigate ligand-dependent GR activation, we treated two ER+ (T47D and ZR-75-1) and two ER- (TN) breast cancer cell lines (MDA-MB231 and HS578T) with GR agonist (dexamethasone, dex) with and without GR antagonist (mifepristone, mif). Here, NR3C1 is linked to breast cancer.